Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Pradaxa | Dabigatran etexilate | Thromboembolism (venous), prevention | Do not list | Complete | ||
Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
Prevymis | letermovir | Cytomegalovirus infection, prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | ||
Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Withdrawn | |||
Prexige | Lumiracoxib | Osteoarthritis (Knee) | Do not list | Complete | ||
Prezcobix | Darunavir/cobicistat | HIV Infection | List with criteria/condition | Complete | ||
Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Prezista | Darunavir | HIV (treatment naive) | List with clinical criteria and/or conditions | Complete | ||
Prezista | Darunavir | HIV infection (Pediatric) | List with clinical criteria and/or conditions | Complete | ||
Pristiq | Desvenlafaxine succinate | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
Probuphine | buprenorphine hydrochloride | Opioid drug dependence, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Procysbi | cysteamine bitartrate | Nephropathic cystinosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Proleukin | Aldesleukin (IL-2) | In-transit Melanoma | Reimburse | Complete | ||
Prolia | Denosumab | Osteoporosis, postmenopausal women | List with clinical criteria and/or conditions | Complete | ||
Prolia | Denosumab (Drug Plan Submission) | Osteoporosis, men | List with clinical criteria and/or conditions | Complete | ||
Prolia | Denosumab | Osteoporosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Qinlock | ripretinib | Gastrointestinal stromal tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
Quinsair | Levofloxacin | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections | Reimburse with clinical criteria and/or conditions | Complete | ||
Qulipta | atogepant | Migraine, prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
Qulipta | atogepant | Migraine, prevention | Reimburse with clinical criteria and/or conditions | Active | ||
Quviviq | daridorexant | Insomnia | Pending | |||
Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Radicava | edaravone | Amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete |